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PTATE-OF-THE-ART PAPERS
otential Hazards and Technical Considerations
ssociated With Myocardial Cell Transplantation
rotocols for Ischemic Myocardial Syndrome
tsik Ben-Dor, MD, Shmuel Fuchs, MD, Ran Kornowski, MD, FACC
el Aviv, Israel
Cell transplantation has recently emerged as a promising therapeutic approach to ischemic
cardiomyopathy syndromes. Clinical studies suggest important benefits, including improved
myocardial perfusion and function. The safety profile so far seems to be high overall, although
the technique may harbor several adverse effects, such as ventricular arrhythmia, acceleration
of atherosclerosis or restenosis, and induction of ischemic events. Multiple factors may affect
the safety of cell infusion into the diseased heart, including the mode of delivery, the type of
cells injected, compound characterization, and the heart status, function, and arrhythmogenic
potential. Also, any adjunctive treatment used to enhance cellular homing and/or transdif-
ferentiation increases the likelihood of unexpected local or systemic toxicity or side effects. In
the present review, we discuss the potential hazards of this novel treatment and its
relationship to technical considerations. (J Am Coll Cardiol 2006;48:1519–26) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.058the American College of Cardiology Foundation
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rntramyocardial cell transplantation has recently emerged as
promising therapeutic approach to ischemic cardiomyop-
thy syndromes. Its goals are to safely reduce cardiac-related
ymptoms and improve cardiac perfusion and function (1,2).
he concept of cell therapy has been examined in animal
odels and has already been introduced into the clinical
rena (3–7). Given the fact that cell therapy, despite
ultiple small clinical studies, should be considered in its
nfancy, further investigation should be carefully planned
gainst its potential hazards.
Multiple factors may affect the safety of cell delivery into
he diseased heart (Fig. 1): 1) the mode of delivery:
ntravenous, intracoronary, intramyocardial (percutaneous
r direct surgical injection), or retrograde myocardial trans-
enous; 2) the cell type: bone marrow-derived stem cells
endothelial progenitor cells, hematopoietic stem cells, mes-
nchymal stromal cells), skeletal myoblasts, or embryonic
tem cells; 3) compound characterization: cell dose and
olume, rate of injection, and quality control of cellular
roducts; 4) the heart status, function, and arrhythmogenic
otential; 5) the time of treatment in relation to the
yocardial injury and/or ischemic insult; and 6) the adjunc-
ive treatment used to enhance cellular homing and/or
ransdifferentiation. In the present review, we discuss the
ossible risks of this novel treatment and their relationship
o technical considerations.
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ntracoronary injection. The use of bone marrow cell
mplantation was introduced in humans in the wake of
ndings of myocardial angiogenesis and/or regeneration in
everal animal models. Its current safety profile and other
elevant clinical data are based on limited clinical experience
n a small number of patients. No long-term consequences
ave yet been evaluated (8 –10). Furthermore, some patients
ith acute myocardial infarcts were treated with intracoro-
ary delivery of bone marrow cells at the time of reperfusion
f the occluded vessel, even before comprehensive animal
ata were available (3–7).
In 2004, Vulliet et al. (11) reported that injection of
esenchymal stromal cells into the coronary artery of
ealthy dogs resulted in augmented myocardial ischemia, as
ndicated by ST-segment elevation and T-wave changes, as
ell as frequent ventricular arrhythmia and troponin I
levation. Histopathologic assessment confirmed the pres-
nce of microinfarction. Moelker et al. (12) noted similar
icroinfarctions within the target tissue in a pig model after
ntracoronary injection of human umbilical cord blood–
erived somatic stem cells. In another study, intracoronary
elivery of mesenchymal stem cells in pigs was associated
ith decreased distal blood flow (13). In human studies
3–7), the combined experience from more than 100 pa-
ients with recent myocardial infarction suggested that
ransplantation of bone-marrow-derived adult progenitor
ells by intracoronary infusion was both feasible and safe.
here was no excessive myocardial damage (e.g., repeated
levation of troponin) or adverse systemic inflammatory
esponse related to the injection (e.g., elevation of
-reactive protein), and there were no deaths, malignant
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Hazards of Myocardial Cell Transplantation October 17, 2006:1519–26rrhythmias, or arrhythmias induced by electrophysiological
tudies during the post-discharge follow-up (range 3 to 12
onths). However, in a pilot study of 6 patients with
schemic cardiomyopathy who received intracoronary infu-
ion of mononuclear autologous bone marrow cells, 1 patient
cquired hypotension with troponin elevation, probably be-
ause of microembolization of the cellular compound (14).
Interestingly, Kang et al. (15) noted excessive restenosis
ates after the intracoronary infusion of peripheral blood–
erived mononuclear cells enriched by granulocyte–colony-
timulating factor (G-CSF) in a small group of patients
ith recent myocardial infarction treated with angioplasty
f the infarct-related artery (15). Similarly, in another
linical trial (16), infusion of a selected subpopulation of
one marrow CD133 cells into the infarct-related artery
as associated with significant in-stent restenosis at the
-month follow-up in 7 of 19 patients. Two patients
howed complete reocclusion, and 2 acquired new lesions in
he infarct-related artery. This rate was significantly greater
han the rate in patients treated with placebo. Furthermore,
ansour et al. (17) recently reported that intracoronary
dministration of hematopoietic bone marrow stem cells
eemed to be associated with accelerated progression of
istal atherosclerosis in the infarct-related artery. Other
tudies, however, showed no relationship between intra-
oronary injection and increased rate of restenosis or accel-
rated atherosclerosis (5), or between G-CSF administra-
ion and restenosis (18,19). This discrepancy is exacerbated
y the absence of reassuring animal data and the emerging
afety controversy concerning cellular and cytokine com-
ounds (for more details, see the section on Adjunctive
reatment), and it underscores the need for planning
ppropriate safety end points. Additional red flags were
aised by Schachinger et al. (4) in their 1-year follow-up
tudy, in which 2 patients (3.4%) treated for myocardial
nfarction by intracoronary cell injection sustained stent
hrombosis. It remains unclear whether this complication
as related to the repeated low-pressure balloon inflations
erformed at the site of the previously implanted stent, at a
ime when stent endothelialization was still minimal and
ragile. If confirmed in larger studies, a change in injection
echnique may be necessary to avoid further intracoronary
ndothelial damage.
The recent discovery that circulatory cells are capable of
ifferentiating into vascular structures (20) highlights the
eed for angiographic follow-up of patients treated with
rogenitor stem-cell infusions. In addition, researchers have
Abbreviations and Acronyms
G-CSF  granulocyte colony-stimulating factor
GM-CSF  granulocyte-macrophage colony-stimulating
factor
VEGF  vascular endothelial growth factoround that angiogenesis and inflammation play an impor-
s
eant role in atherosclerotic plaque formation and that lesion
xpansion and may accelerate the coronary atherosclerosis
hat occurs after infusion of progenitor cells (21).
These studies underscore the cautious approach necessary
o the use of intracoronary stem-cell infusion in humans.
afety assessments in humans must account for the small
iameters of the bone marrow and progenitor cells used in
linical studies (10 to 12 m) compared with the mesen-
hymal stromal cells or umbilical cord blood–derived so-
atic stem cells (20 m) that caused microinfarctions in
nimals (11–13). Also, freshly aspirated cells are smaller
han processed cells (11). In addition, parameters such as
ell dose and concentration, compound viscosity, and rate of
oronary infusion may have important impacts on the safety
f the treated myocardium, as may the status of the recipient
issue, because ischemic myocardium may differ in micro-
esponses and/or macroresponses from infracted myocar-
ium. Thus, clinical research needs to be carefully planned
ith selection of the appropriate delivery method as well as
ell population and dosing parameters that may carry the
est risk-to-benefit profile.
ntramyocardial injection. Intramyocardial delivery of
herapeutic substances can be achieved by either direct
njection after open-chest thoracotomy (transepicardial) or
atheter-based techniques (transendocardial) using electro-
echanical mapping or fluoroscope guidance (22). Our
roup previously examined the safety of the electromechan-
cally guided injection catheter system in porcine hearts
23,24). There were no cases of sustained arrhythmia, and
o gross evidence of cardiac perforation, peripheral embo-
ization, or stroke. However, in some of the injection sites,
he endocardial injury seemed to be exaggerated. These
njuries could be classified into 3 types: 1) type A injury
ncluded the desired formation of endomyocardial slots
ombined with microscopic tracks of hemorrhagic infiltration
urrounded by the injected compound (Figs. 2A and 2B); 2 )
ype B injury induced the formation of endocardial ecchy-
igure 1. Factors influencing cell therapy. EPCs  endothelial progenitor
ells; FGF  fibroblast growth factor; G-CSF  granulocyte colony-
timulating factor; GM-CSF  granulocyte-macrophage colony-
timulating factor; HIF  hypoxia inducible factor; VEGF  vascular
ndothelial growth factor.
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October 17, 2006:1519–26 Hazards of Myocardial Cell Transplantationosis caused by an exaggerated or forceful injection (Fig.
C); 3) type C was a transmyocardial injury with possible
eterioration to myocardial perforation and pericardial tam-
onade, also related to an excessive injected volume (Figs.
D and 2E). Similar to our findings, other data derived
rom animal (25) and human (26 –28) studies indicated no
rrhythmia, infection, myocardial inflammation, increased
brosis, or perforation caused by catheter-based techniques
24). In addition, in a report by Dohmann et al. (29) on the
ostmortem findings on a single patient after transendocar-
ial injection of bone-marrow-derived mononuclear cells,
here was no abnormal or disorganized tissue growth, no
bnormal vascular growth, and no enhanced inflammatory
eaction in the heart.
By contrast, Kastrup et al. (30) reported direct injury from
ntramyocardial injection of vascular endothelial growth
actor (VEGF) in 5 patients (6.25%) with severe stable
ngina who participated in the Euroinject One study.
omplications included pericardial tamponade, high-degree
igure 2. (A) Endomyocardium showing spread of injected methylene blue
ye tracer. (C) Endocardial ecchymosis resulting from intramyocardial injtrioventricular block, ST-segment elevation, myocardial mnfarction, embolic events, and sepsis, all of which were
rocedure related and independent of the injected com-
ound. These findings emphasize the importance of tech-
ical considerations, especially in infrequently used proce-
ures, and they may be minimized by careful patient
election and preprocedural assessment by different imaging
odalities. Detailed patient notification of the potential
rocedure-related risks is mandatory.
Regardless of the delivery method, the local effects of the
ransplanted cells must be thoroughly considered. These
nclude exaggerated inflammation or aberrant tissue forma-
ion that might impair myocardial function. Yoon et al. (31)
howed that direct transplantation of unselected bone mar-
ow cells into the acutely infracted myocardium of murine
earts may induce significant myocardial calcification in
oth infarcted and normal myocardial regions. Similarly,
ransplanted undifferentiated mesenchymal stem cells have
een shown to develop into fibroblastic scar tissue (9). Li
t al. (32) did not find calcification after injection of bone
B)Gross pathology of cross-sectioned hearts injected with methylene-blue
of methylene blue. (D and E) Epicardial staining with methylene blue.arrow cells in dogs, although there were fibrotic changes
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Hazards of Myocardial Cell Transplantation October 17, 2006:1519–26ithin the myocardium that could have been cell- or
njection-related. Stamm et al. (33) treated 6 patients after
ecent (3 months) myocardial infarction with bone-
arrow-derived CD133 cells during coronary artery by-
ass surgery. Supraventricular arrhythmia developed in 2
atients, and pericardial effusion developed in 2 patients.
owever, the lack of a control group and the small number
f patients precluded a definitive conclusion regarding a
ause-and-effect relationship. Other studies (34 –36) of local
tem cell transplantation during open-heart surgery reported
n absence of clinically relevant inflammatory responses or
yocardial damage or aberrant tissue formation. We re-
ently studied 27 patients with refractory myocardial ische-
ia who underwent transendocardial injection of autolo-
ous unfractionated bone marrow cells (37). The 1-year
urvival rate was 100%, although 7 patients (26%) required
n additional revascularization procedure (angioplasty or
ypass surgery). Interestingly, in 5 of these patients, the
ntervention was performed in a vessel supply remote from
he injected territory because of late restenosis and disease
rogression. Again, as no control group was used, we could
ot determine whether these processes were accelerated by
he cell injection or were part of the natural history of the
nderlying disease. Nevertheless, this observation under-
cores the potential need for angiographic follow-up of
atients undergoing experimental cellular transplantation
rotocols to exclude accelerated coronary atherosclerosis and
ate restenosis.
eart arrhythmic potential. Most of the candidates for
xperimental stem cell strategies are patients with heart
ailure, previous myocardial infarction, and severe myocar-
ial ischemia, and all are at considerable risk of arrhythmia
nd sudden cardiac death.
However, studies of intramyocardial skeletal myoblast injec-
ion during coronary bypass surgery or by catheter-based
echnique in patients with depressed ischemic cardiomyopa-
hy have shown a high incidence of serious ventricular
able 1. Incidence of Serious Ventricular Arrhythmias With Intr
Study
Patients
(n)
Procedure/
Target Tissue*
Revascularization
of Injected
Segments
enasche et al. (38) 10 CABG
EF 35%
Scar
No
mits et al. (39) 5 EF 20%– 45%
Scar
No
mits et al. (39) 8 NA No 
iminiak et al. (40) 9 EF 25%– 45%
Scar
No
hachques et al. (41) 20 CABG
EF 28%
Scar, peri-scar
Yes
erreros et al. (71) 12 CABG
EF 35%
Scar, peri-scar
YesPatient population refers to the global function of myocardium and performance of cell tr
CABG  coronary artery bypass grafting; EF  ejection fraction; NA  not availablerrhythmia (Table 1), whereas studies using bone-marrow-
erived cells did not (Table 2). Menasche et al. (38)
eported on 10 patients with a severely reduced ejection
raction who underwent coronary artery bypass grafting and
yoblast injection into scar myocardial tissue that was
upplied by a totally occluded vessel and could not receive a
urgical graft. Four patients had sustained ventricular tachy-
ardia at 11 to 22 days after the procedure, of whom 2 had
dditional episodes of ventricular arrhythmias 5 and 9
onths later. All 4 patients required an implantable defi-
rillator. Smits et al. (39) treated 5 patients with severe
eart failure caused by anterior myocardial infarction with
ransendocardial injection of myoblasts as the sole proce-
ure. One patient had ventricular tachycardia 6 weeks later
nd required an implantable defibrillator, and 8 patients had
episodes of sudden death and 3 events of ventricular
achycardia. In another study, episodes of ventricular tachy-
ardia were observed in 1 of 9 patients with ischemia-driven
eart failure treated by retrograde transcoronary venous
yoblast injection (40). Collectively, these studies suggest
n arrhythmogenic potential of direct myocardial injection
f myoblasts into scar tissue irrespective of the delivery
echnique. An alternative suggestion was made by
hachques et al. (41), who noted no serious arrhythmias in
0 patients over a mean follow-up period of 14 months after
njection of myoblasts expended in an autologous medium
ather than fetal bovine serum. This technique was based on
he assumption that trace contamination with xenogeneic
roteins can provoke arrhythmias because of an immune
i.e., rejection-type) reaction at the injection site. Fuchs
t al. (37) found that the injection of bone marrow– derived
ells was safe in patients with preserved left ventricular
unction. In another study in 14 patients with severely
educed left ventricular function caused by ischemic cardio-
yopathy, the injection of bone marrow–derived mononu-
lear cells did not induce early arrhythmia, but 1 patient
uffered sudden cardiac death 14 weeks after treatment (27).
cardial Transplantation of Skeletal Myoblasts
ode of
njection
No. of Cells
(Mean  106)
Follow-Up
(Months)
Serious
Ventricular
Arrhythmia (n)
SCD
(n)
epicardial 871 10.9 4 (40%) 0
endocardial 296 6 1 (20%) 0
endocardial NA 3 3 (37.5%) 2 (25%)
coronary-
ous
57 6 1 (11.1%) 0
epicardial 300 14 0 0
epicardial 211 3 0 0amyo
M
I
Trans
Trans
Trans
Trans
ven
Trans
Transansplant concomitant with CABG. Scar or peri-scar refers to the injection site.
; SCD  sudden cardiac death.
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October 17, 2006:1519–26 Hazards of Myocardial Cell TransplantationThus, malignant arrhythmias are apparently more likely
o occur after myoblast transplantation than after bone
arrow cell injection, especially when the cells are injected
irectly into nonviable (scar) tissue. It is conceivable that
ack of gap junction formation between the myoblasts and
ardiomyocytes may serve as a substrate for the formation of
 re-entry cycle and resultant ventricular arrhythmia (42).
outs et al. (43) recently reported that skeletal myoblasts
njected into the scar of a myocardial infarction do not
ignificantly alter impulse propagation (which is already
ltered by the scar tissue) or induce greater arrhythmia
ompared with the myocardial infarction alone. However, in
iable myocardium, skeletal myoblasts can affect impulse
ropagation through pacing from the epicardium, not the
ndocardium. This difference, according to their study, did
ot translate into an increase in arrhythmia events. Alter-
atively, the injected cells themselves, or the local injury/
dema induced by the intramyocardial injection itself, may
ause arrhythmia in already highly susceptible patients.
hang et al. (44) explored the arrhythmogenic potential of
ardiomyocytes derived from pluripotent embryonic stem
ells and embryonal carcinoma cells. The electrical record-
ngs showed that both cell lines manifested spontaneous
ctivity, low dV/dt, prolonged action potential duration,
nd easily triggered arrhythmias. These findings raise con-
erns about the use of stem cells for transplantation therapy
ecause they may act as an arrhythmogenic source via any of
he 3 classic mechanisms: re-entry, automaticity, or trig-
ered activity.
In conclusion, current data suggest that the risk of
rrhythmia occurring after myocardial cell transplantation
ay be increased by several factors: 1) the type of cell
able 2. Incidence of Serious Ventricular Arrhythmia With Myo
lood-Derived Progenitor Cells
Study
Patients
(n)
Procedure or
Event/Target
Tissue*
Revascularization
of Injected
Segments
efs. (3–7,15) 113 Acute MI Yes B
I
erinet et al. (27) 14 Ischemic
EF 40%
No B
T
ilva et al. (28) 5 Ischemic
EF 40%
No B
T
uchs et al. (37) 27 Ischemic
EF 30%
No B
T
tamm et al. (33) 6 CABG
Peri-scar
No B
T
zbaran et al. (34) 6 CABG
EF 25%
Ischemic
Yes C
T
alinanes et al. (35) 14 CABG
Scar
Yes B
T
rchundia et al. (36) 5 CABG
Scar, peri-scar
Yes C
T
Patient population refers to the global function of myocardium and performance of
car or peri-scar refers to the injection site.
BMC  bone marrow cells; BMMNC  bone marrow mononuclear cells; CAB
F  ejection fraction; MI  myocardial infarction; SCD  sudden cardiac death.njected; 2) the local myocardial milieu and electrical prop- mrties of the recipient tissue; 3) the presence of global and
egional left ventricular function; 4) the ex vivo cell-
xpansion technique; and 5) the timing of the transplanta-
ion relative to the ischemic or infarction events.
nregulated differentiation. Bone marrow is a multicel-
ular tissue composed of hematopoietic precursors, their
ifferentiated progeny, and a stromal cell network. The
troma contains a heterogeneous mixture of mesenchymal
tem cells, multipotent adult progenitor cells, adipocytes,
eticulocytes, endothelial cells, fibroblasts cells, and osteo-
lasts, which can differentiate into a variety of nonhemato-
oietic lineages (45– 47). Because the molecular signaling,
nderlying mechanisms, temporal parameters, and local
onditions that control cellular differentiation are still cur-
ently obscure, the potential of uncontrolled differentiation
f the injected cells is a major concern. For example,
mbryonic stem cell transplantation has been associated
ith teratoma formation (48), and the cells were found to
how chromosomal abnormalities (49). Others noted a
ossible association of high levels of circulating endothelial
rogenitor cells and the risk of certain cancers, such as
ultiple myeloma (50), which might be caused by angio-
enic effects (51). However, as of today, no clinical studies
ave suggested the formation of aberrant tissue, enhance-
ent of scar formation, or induction of tumor growth.
DJUNCTIVE TREATMENT
he systemic administration of cytokines to accelerate cell
obilization, homing, and/or transdifferentiation has been
ested in many preclinical and clinical studies (52–54). This
echnique is potentially hazardous because of the cytokine’s
al Cell Transplantation of Bone Marrow Cells or Circulating-
Type and
ode of
jection
No. of Cells
(Mean  106)
Follow-Up
(Months)
Serious
Ventricular
Arrhythmia (n)
SCD
(n)
NC, CPC
oronary
1.5–33.6 3–12 0 0
NC
endocardial
25.5 4 0 1 (7.1%)
NC
endocardial
NA 6 0 0
NC
endocardial
28 12 0 0
(AC133)
epicardial
1.5 9–16 0 0
(CD34)
epicardial
32.6 4–10 0 0
CD34/117
epicardial
31.5 10 0 0
CD34
epicardial
20 7 0 0
nsplant concomitant with treatment of acute MI, ischemic myocardium, or CABG.
coronary artery bypass grafting; CPC  circulating-blood-derived progenitor cells;cardi
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Hazards of Myocardial Cell Transplantation October 17, 2006:1519–26f prothrombotic effects on both coagulation proteins and
latelets (55,56). The administration of granulocyte–
acrophage colony-stimulating factor (GM-CSF) in a rat
odel was found to facilitate infarct expansion and left
entricular remodeling (57), and in humans, sporadic cases
f myocardial infarction were reported in cancer patients
nd in healthy subjects receiving G-CSF (58–63). The
-CSF also increased levels of C-reactive protein in healthy
ubjects (64) and caused cardiac ischemia and infarction in
atients with severe coronary disease (65).
The safety of G-CSF and GM-CSF administration as an
djunct to cell injection has been examined (Table 3),
lthough the findings are still controversial. Kang et al. (15)
eported that G-CSF administration with or without
ononuclear cell injection aggravated in-stent restenosis in
of 10 patients after acute myocardial infarction treated by
tent-based angioplasty. Boyle et al. (66) described a patient
n whom acute coronary syndrome developed 2 months after
-CSF mobilization of CD34 cells. Others, however,
ound no association of G-CSF administration and reste-
osis in patients with acute myocardial infarction who
nderwent successful percutaneous intervention (18,19,67).
he high rate of in-stent restenosis reported by Kang et al.
15) compared with the other studies (18,19,67) could result
rom different patient populations (non–ST-segment elevation
yocardial infarction vs. ST-segment elevation myocardial
nfarction) with different sequence protocols (G-CSF treat-
ent before or after coronary intervention).
An additional concern is that G-CSF, because of its
hrombogenic and inflammatory properties, may accelerate
laque instability and coronary thrombogenicity. Powell
t al. (68) reported that G-CSF administration in 16 pa-
ients with severe coronary artery disease mobilized hema-
opoietic progenitor cells into circulation without adverse
ffects. However, 2 of the patients with advanced disease
nd recurrent ischemia experienced serious adverse events,
amely, non–ST-segment elevation and myocardial infarc-
ion at 8 h after the fifth G-CSF dose, and fatal myocardial
nfarction 17 days after treatment (69). In another study,
-CSF administration improved physical performance in
6 patients with chronic heart failure, but a subgroup of
atients with ischemic cardiomyopathy had cardiac side
ffects, including episodes of dyspnea or angina that occa-
ionally coincided with particularly high leukocyte counts;
here was 1 episode of fatal ventricular fibrillation (70).
hus, the overall safety profile of G-CSF, especially in
atients with coronary disease, is of concern, and its efficacy
s questionable at best.
uality control of cellular products. Most cellular com-
ounds used today are autologous, although some studies of
llogenic cells have recently been initiated. Although allo-
enic cell compounds must be prepared under stringent
aboratory conditions, autologous cell preparation is not
tandardized, especially when the cells are to be injected
oon after harvesting. Moreover, the angiogenic potential of
utologous cell compounds is not routinely evaluated before Ta
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October 17, 2006:1519–26 Hazards of Myocardial Cell Transplantationheir administration, and the only relatively controlled
arameter is the number of cells. The percentage of sub-
opulations of cells also varies, imposing further complexity
n cell dosing. Those hurdles complicate the ability to assess
he dose-and-effect relationship, a factor of paramount
mportance in the safety and efficacy of therapeutic com-
ounds (71,72).
ummary. Cell transplantation is a promising therapeutic
pproach to ischemic cardiomyopathy syndromes. Clinical
tudies suggest beneficial effects, including improvement of
yocardial perfusion and function. The increasing experi-
nce with these techniques indicates a high safety profile
verall, although they pose several potential dangers, such as
entricular arrhythmia, acceleration of atherosclerosis and
estenosis, and induction of ischemic events. It is important
o underscore that the general adverse event rate is currently
ow, and the specific cases reported were strongly related to
he type of cell injected, the characteristics of the patient
opulation, and the adjunctive use of cytokines. Optimiza-
ion of cell therapy requires not only larger clinical trials, but
lso standardization of cell preparation methods, potency
ssessment, and controlled administration, which together
ay allow for a better assessment of the risk benefit.
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